Extended-lister
Showing 91 - 100 of 10,000 entries
-
Our broad-based risk frameworks, research-driven factor models and popular stress tests can help sharpen your competitive edge by properly assessing contributions to risk and performance, whether your fund strategy is long/short equity, quant, macro, fixed income or something else.
-
Did equity and fixed-income factors perform as expected during the first full quarter of COVID-19’s global spread? Hitendra Varsani, executive director, core equity research, analyzes the results for Q2, and what MSCI’s Adaptive Multi-Factor Allocation Model showed as Q3 kicked off.
-
The global financial crisis of 2008 fundamentally changed global markets. Its impact on investors cannot be overstated. Here we share reflections from leading MSCI researchers discussing what we learned about risk and markets and where they see the investment world heading over the next 10 years.
-
Institutional investors may use single-factor portfolios for a strategic allocation alongside their market-cap investments, or as a tactical play to implement a particular market, factor-valuation, or economic cycle perspective. In both cases, there are certain questions to consider when constructing such portfolios. Abhishek Gupta, executive director on the index solutions research team, walks us through.
-
In this episode of MSCI Real Estate Conversations, Doug Slater, Head of Americas Real Estate Coverage, MSCI was joined by Anthony Wirth, Senior Client Consultant, MSCI to discuss the investment insights gained from his career at CBRE Global investors where he held roles from Director of Americas Research to Head of Analytics prior to joining MSCI this year.
-
Stephane Mattatia, Global Head of Derivatives Licensing and Thematic Indexes at MSCI, Caique Cardoso, ETF Specialist at Itau, Simon Barnett, Director of Life Sciences Research at ARK Invest share their views on how genomics innovation is creating opportunities for investors. These innovations encompass technological and scientific developments in DNA sequencing, gene editing, targeted therapeutics, bioinformatics, and agricultural biology.
-
Assets allocated to ESG investments have boomed in recent years. While some may fear that accelerating allocations could lead to frothy valuations, research so far suggests this is mostly unwarranted. In 2021, we see both hype and skepticism about ESG giving way to acceptance and a more nuanced understanding of when and how ESG has shown pecuniary benefits — and when it hasn’t.
-
Contributor
MSCI Research
-
Case Study
To capitalize on ESG researchA U.S.-headquartered global investment management firm specializing in quantitative investing was seeking a source to enhance its in-depth research capabilities for environmental, social and governance-related business practices of companies worldwide.
-
Contributor
MSCI Index Research